Is ICER Too NICE? A Comparison Of Drug Assessments Programs
Drug companies are accusing the US Institute for Clinical and Economic Review of approaching cost effectiveness assessments in the same way as the UK National Health Service gatekeeper, the National Institute for Health and Care Excellence.
You may also be interested in...
Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.
Numerous value frameworks launched over the past few years have encouraged acceptance of cost effectiveness assessments in the US and ICER's influence in the field is growing. Employers may be the next group to promote the concept.
Institute for Clinical and Economic Review issues final cost effectiveness report on psoriasis agents that improves the value rating earlier assigned to novel treatments based on a consideration of actual net prices.